Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kura Oncology, Inc. ( KURA ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDT

We are now a fully integrated research, development and commercial company. In the last quarter, we announced our second full quarter of sales for KOMZIFTI, which is our menin inhibitor approved in relapsed/refractory NPM1 mutant AML. We were really pleased to say that we took leadership of new patient starts in our second full quarter. That's pretty unusual. We continue to push the launch, and we have a large development program behind that initial approved indication. We have 2 Phase III trials ongoing in both the intensive chemotherapy and non-intensive chemotherapy settings with ziftomenib, which is KOMZIFTI.